Background and Objectives Although buprenorphine/naloxone is widely recognized as first‐
line therapy for opioid use disorder, the requirement for moderate withdrawal prior to …

Buprenorphine is an effective medication for the treatment of opioid use disorder. However,
the traditional method of buprenorphine induction requires a period of abstinence and the …

Background Prerequisite opioid withdrawal symptoms prior to buprenorphine induction are
unacceptable to many patients. We assessed whether transdermal buprenorphine …

Background Methadone, a full opioid agonist, and buprenorphine, a partial agonist at the
opioid receptor, are established first-line medications for opioid maintenance therapy …

Objectives To describe 2 case reports in which high-dose administration of sublingual
buprenorphine/naloxone quickly stabilized fentanyl users who presented to the hospital. To …

Buprenorphine induction can lead to precipitated opioid withdrawal, even when using novel
techniques such as transdermal buprenorphine. Involuntary limb movements are a …

Aims Buprenorphine is marketed in a sublingual formulation for treatment of opioid
dependence. A transdermal formulation has been developed that may provide extended …

BACKGROUND Buprenorphine is a partial opioid agonist with high binding affinity at the mu-
opioid receptor. If buprenorphine is given while full opioid agonists occupy the mu-opioid …

Despite proven clinical utility, use of sublinugual buprenorphine is fraught with issues of
potential diversion among patients with opioid dependence. Transdermal buprenorphine …

Background and Objectives Individuals exposed to fentanyl are at risk of precipitated
withdrawal using typical buprenorphine/naloxone induction procedures. Methods This case …